Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2016
July 2016, Vol 7, No 6
July 2016, Vol 7, No 6
No Benefit from Nephrectomy in High-Risk Renal-Cell Carcinoma with Thrombus
By
Charles Bankhead
Genitourinary Cancers
July 2016, Vol 7, No 6
High-risk patients with metastatic renal-cell carcinoma (RCC) and venous tumor thrombus derived no benefit from cytoreductive nephrectomy and should be evaluated for clinical trials of systemic therapy, suggested a retrospective multicenter review.
Read Article
In the Literature - July 2016
In the Literature
July 2016, Vol 7, No 6
Read Article
FDA Streamlines Expanded Access Application for Patients to Get Investigational Drugs
By
Nick Bryant
Health Policy
,
Policies & Guidelines
July 2016, Vol 7, No 6
The Individual Patient Expanded Access Application, which is designed to streamline the application procedure for individual patients who apply for expanded access to investigational therapeutics, including expanded access to drugs that are not in clinical trials, was recently updated by the FDA. Form FDA 3926 authorizes expanded access to investigational drugs for patients with serious or life-threatening conditions who have no therapeutic options.
Read Article
Proposed Reductions to Medicare Drug Payments Will Hurt Patients, Small Practices
By
Jessica Miller
Health Policy
,
Policies & Guidelines
July 2016, Vol 7, No 6
Opposition to proposed changes to the Medicare Part B payment for prescription drugs continues to grow since the Centers for Medicare & Medicaid Services (CMS) announced its plan in March 2016.
Read Article
Palliative Care Requires a Team Approach
By
Wayne Kuznar
Palliative Care
,
Personalized Medicine
July 2016, Vol 7, No 6
Early intervention utilizing a team approach is important to successful palliative care, agreed a multidisciplinary panel convened at the 2016 National Comprehensive Cancer Network (NCCN) annual conference.
Read Article
Incorporating Patient and Employer Perspectives into Value-Based Cancer Therapy Decision-Making
By
Joseph P. Fulginiti, PharmD
;
Melissa S. Pavilack, PharmD
Employers’ Perspective
,
Value-Based Care
,
Value Peer-spectives
July 2016, Vol 7, No 6
“Value” in healthcare has been defined as outcomes relative to cost. Determining the value of a healthcare benefit remains difficult and complex for many stakeholders. With the increasing cost of cancer therapies, value has become an important topic of conversation for patients, healthcare providers, self-funded plan sponsors (employers), and payers.
Read Article
Adding Daratumumab to the Treatment Regimen Improves Progression-Free Survival in Patients with Multiple Myeloma
By
Jessica Miller
Hematologic Malignancies
,
Multiple Myeloma
July 2016, Vol 7, No 6
Daratumumab in combination with lenalidomide and dexamethasone achieved a 63% reduction in progression-free survival (PFS) compared with lenalidomide and dexamethasone alone in patients with multiple myeloma who had received at least 1 previous line of therapy, according to study results presented at the 2016 European Hematology Association Annual Congress meeting.
Read Article
New Oncology Care Model Focuses on Payment Reform and Value-Based Care
By
Jessica Miller
Health Policy
,
Value-Based Care
,
Policies & Guidelines
July 2016, Vol 7, No 6
A new payment and delivery model introduced by the Center for Medicare & Medicaid Innovation aims to align financial incentives to improve oncology care and outcomes. Expected to begin in July 2016, the program will target patients from the start of their chemotherapy through 6 months of care.
Read Article
Opportunities for Shared Decision-Making in Clinical Practice
By
Chase Doyle
Value in Oncology
July 2016, Vol 7, No 6
The National Academy of Medicine recommends a shared decision-making approach when discussing medical treatments; however, an overview of evidence presented by Terrance Lynn Albrecht, PhD, Associate Center Director, Population Sciences, Karmanos Cancer Institute, and Chief of Oncology, Wayne State University School of Medicine, Detroit, at the 2016 American Society of Clinical Oncology annual meeting suggests that clinicians are not very effective in following this recommendation.
Read Article
Liquid Biopsies Show High Correlation with Tissue Biopsy for Genetic Mutations
By
Wayne Kuznar
Personalized Medicine
July 2016, Vol 7, No 6
With the exception of resistance mutations, somatic alterations in circulating tumor (ct) DNA (ie, a liquid biopsy) are consistent with alterations found in tissue biopsies of patients with advanced solid tumors, said Philip C. Mack, PhD, Director of Molecular Pharmacology, University of California Davis Comprehensive Cancer Center, Sacramento, at the 2016 American Society of Clinical Oncology (ASCO) annual meeting.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma